Evidence map›Paper›PMID 35974297›Full record

ArticleThe international journal of neuropsychopharmacology2022

Region-Specific Enhancement of c-fos Expression by Combined Treatment With NMDA Receptor Agonists and Antagonists With Antidepressant Potential.

Andrei-Nicolae Vasilescu, Natascha Pfeiffer, Federica Terraneo, Marco Andrea Riva, Undine E Lang, Dragos Inta, Peter Gass

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Andrei-Nicolae VasilescuRG Animal Models in Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, Mannheim Faculty, Heidelberg University, Mannheim, Germany.ORCID 0000-0003-2594-3964
Natascha PfeifferRG Animal Models in Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, Mannheim Faculty, Heidelberg University, Mannheim, Germany.
Federica TerraneoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Marco Andrea RivaDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Undine E LangDepartment of Psychiatry (UPK), University of Basel, Basel, Switzerland.
Dragos IntaRG Animal Models in Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, Mannheim Faculty, Heidelberg University, Mannheim, Germany.
Peter GassRG Animal Models in Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, Mannheim Faculty, Heidelberg University, Mannheim, Germany.
Heidelberg University · DEUniversity of Milan · ITUniversity of Basel · CHUniversity of Fribourg · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapastinel, formerly Glyx-13, is a novel positive allosteric modulator of the N-methyl-D-aspartate-receptor (NMDAR) that counteracts psychotomimetic actions of NMDAR antagonists. We set out to evaluate the effect of rapastinel alone or in combination with the global and GluN2B subunit-specific NMDAR antagonists MK-801 and Ro25-6981, respectively, on neuronal activation in relevant regions using c-fos brain mapping. Whereas rapastinel alone did not trigger significant c-fos expression beyond the prelimbic cortex, it strongly increased the c-fos expression induced by MK-801 in hippocampal, cingulate, and retrosplenial areas. Similar results were obtained when rapastinel was replaced by D-cycloserine. Our results reveal new interactions at network level between NMDAR modulators with possible implications regarding their therapeutic effects.

Indexed as

Dizocilpine MaleateReceptors, N-Methyl-D-AspartateAntidepressive AgentsExcitatory Amino Acid AntagonistsProto-Oncogene Proteins c-fosAntidepressive AgentsDizocilpine MaleateExcitatory Amino Acid AntagonistsProto-Oncogene Proteins c-fosReceptors, N-Methyl-D-Aspartateantidepressant drugD-CycloserineMK-801NMDA receptorsRapastinel

Identifiers

PMID35974297
PMCPMC9670745
OpenAlexW4292170380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.